Semaglutide and Low Blood Pressure: What Clinical Evidence Shows

What the trial data actually recorded about blood pressure

The clearest evidence comes from the STEP 1 trial, published in the New England Journal of Medicine. Over 68 weeks, adults treated with semaglutide 2.4mg lost an average of around 15% of body weight. Systolic blood pressure fell by a meaningful margin in the treatment group, roughly 6 mmHg more than in the placebo group. That reduction is clinically significant: it sits in the same territory as adding a low-dose antihypertensive medicine. Importantly, the trial enrolled people with obesity but without type 2 diabetes, meaning the blood pressure effect reflects the weight-loss mechanism rather than any glucose-lowering action.

Diastolic pressure also fell, though by a smaller amount. These findings are consistent across the broader semaglutide programme and are now reflected in NICE's appraisal of semaglutide for weight management (TA875), which notes cardiovascular risk factors improving alongside weight. If you are wondering whether semaglutide can raise blood pressure rather than lower it, the directionality of the evidence is clear: semaglutide lowers blood pressure far more often than it raises it, and frank hypotension is not in the common-side-effect profile.

If you want to explore how this plays out in practice, the page on Wegovy and blood pressure covers the cardiovascular picture in more detail.

Why low blood pressure can still become relevant during treatment

The risk of blood pressure falling too far is indirect rather than pharmacological. Semaglutide reduces appetite considerably, most people eat less, drink less, and lose weight at a pace that can outstrip their existing medication regimen. Someone taking two antihypertensives whose systolic pressure was borderline-high before treatment may find it sitting in the low-normal range six weeks later. That is not an emergency, but it is a clinical signal.

Dizziness and light-headedness do appear in the Wegovy prescribing information, and they are most common after starting treatment or stepping up the dose. A good rule of thumb from our clinical team: if you feel dizzy when you stand up (particularly first thing in the morning) tell your prescriber promptly rather than waiting for your next scheduled review. Postural (orthostatic) hypotension, where pressure drops briefly on standing, can mimic GI symptoms and catch people off guard.

Dehydration compounds the picture. Nausea and reduced appetite mean some people take in less fluid than usual, particularly in the first few weeks. The NHS medicines guidance for semaglutide advises contacting a doctor if vomiting or diarrhoea leads to significant fluid loss, in part because dehydration can drop blood pressure independently of the medicine itself. Small sips through the day matter more than people expect.

What this means for people already on blood pressure medication

This is the scenario that warrants the most attention. If you are already prescribed an ACE inhibitor, beta-blocker, calcium-channel blocker or diuretic, your prescriber needs to know before semaglutide begins. It is not a reason to avoid treatment, for many people with obesity-related hypertension it is precisely the combination that eventually allows a medication to be reduced or stopped, under clinical supervision. But it does mean your blood pressure should be monitored more closely in the first weeks.

The semaglutide overview explains how the medicine works more broadly, and our semaglutide testing page covers the checks and monitoring that form part of safe ongoing treatment. For those specifically weighing up Wegovy's cardiovascular effects, our page on whether Wegovy lowers blood pressure goes further into the mechanism. The short version: blood pressure lowering is generally a benefit of treatment, not a hazard, but only if managed with a prescriber who knows your full picture.

Anyone considering treatment can start a free consultation with our clinical team. Your cardiovascular history is part of what a GPhC-registered prescriber at nume reviews before any decision is made.

When to get medical help

Most blood pressure changes on semaglutide are gradual and picked up at routine monitoring. Some situations need attention sooner. Get medical help promptly if you experience: severe or persistent dizziness; fainting or near-fainting; a sudden drop in energy that feels out of proportion to normal tiredness; or symptoms of dehydration (very dark urine, extreme thirst, confusion) alongside GI illness.

If you take blood pressure medicines and your home monitor starts showing readings consistently below 100/60 mmHg, contact your GP or prescriber the same day, not at the end of the week. That is not panic: it is the kind of routine adjustment that makes treatment work safely long-term. You can also read more about how Wegovy affects blood pressure over time and what monitoring looks like in practice.

If you suspect semaglutide or any medicine is causing an unexpected reaction, you can report it via the MHRA Yellow Card scheme, the UK's system for tracking real-world safety signals. Reports from patients matter and are taken seriously.

For anything urgent, call 111 or speak to your GP. Our aftercare team is available seven days a week for questions that aren't emergencies but won't wait until Monday morning.